CYTK Cytokinetics Inc
$73.94 +2.73%
Updated
Healthcare · Pharmaceutical Preparations
Cytokinetics Inc (CYTK) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $10.3 billion. Shares last traded at $73.94, 18.7% below their 52-week high. Over the past year the stock is up 47.8%. Revenue grew 376.6% year over year.
Market Cap
$10.3B
Shares Out
139.0M
EPS (TTM)
$-12.37
P/E Ratio
—
P/S Ratio
151.90
P/B Ratio
—
Dividend / Share
—
Dividend Yield
—
52-Week High
$91.00
52-Week Low
$47.22
Volume
98,184
Avg Vol (3m)
115,825.286
Performance
1W
-5.14%
1M
-6.25%
3M
+2.28%
6M
+18.83%
YTD
+19.70%
1Y
+47.84%
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
44.10
SMA (50)
$79.25
SMA (200)
$69.71
Price vs SMA50
-6.70%
Price vs SMA200
+6.07%
ATR (14)
$3.09
Financials
Revenue
$68M
Net Income
$-894M
Gross Margin
—
Operating Margin
—
Net Margin
—
Return on Equity
515.3%
Return on Assets
-46.5%
Current Ratio
6.66
Debt / Equity
-1.43
Revenue Growth (YoY)
+376.6%
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $-3.17 | 2026-08-06 |
| Q1 2026 | $-1.67 | 2026-05-05 |
| FY 2025 | $-6.54 | 2026-02-26 |
| Q3 2025 | $-5.04 | 2025-11-05 |
| Q2 2026 | $-2.49 | 2026-08-06 |
| Q1 2026 | $-1.36 | 2026-05-05 |
Pharmaceutical Preparations peers
CYTK vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated
P/S vs peers
151.90 / 11.11 med
+1268% premium
1–14 of 14
| LLY | Lilly (Eli) | $1.09T | 40.86 | 13.70 | 33.5% | -0.02% |
| JNJ | Johnson & Johnson | $670.6B | 31.88 | 6.85 | 21.5% | +1.04% |
| ONC | Beone Medicines Ltd. | $535.9B | 817.25 | 87.43 | 10.7% | +0.23% |
| ABBV | AbbVie | $459.8B | 72.87 | 7.14 | 9.8% | -0.57% |
| MRK | Merck | $375.8B | 118.44 | 5.65 | 4.8% | +0.44% |
| ABT | Abbott Laboratories | $189.5B | 30.20 | 4.20 | 13.9% | -1.50% |
| PFE | Pfizer | $164.2B | 37.91 | 2.58 | 6.8% | -0.76% |
| VRTX | Vertex Pharmaceuticals | $141.5B | 32.11 | 11.24 | 35.0% | +0.24% |
| BMY | Bristol Myers Squibb | $139.1B | 14.98 | 2.83 | 18.9% | +0.62% |
| REGN | Regeneron Pharmaceuticals | $87.2B | 20.15 | 5.61 | 27.9% | -1.02% |
| TEVA | Teva Pharmaceutical Industries Ltd | $42.6B | 60.41 | 2.46 | 4.1% | -2.32% |
| ALNY | Alnylam Pharmaceuticals | $35.4B | 43.77 | 9.52 | 21.8% | -1.10% |
| ZTS | Zoetis | $31.5B | 12.05 | 3.31 | 27.5% | +0.16% |
| RPRX | Royalty Pharma Plc | $28.2B | 34.56 | 11.11 | 32.1% | +1.24% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.